Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Int J Pharm. 2020 Oct 15;588:119778. doi: 10.1016/j.ijpharm.2020.119778. Epub 2020 Aug 15.
Vinpocetine (VNP), a semisynthetic drug, is utilized for the treatment of cerebrovascular and memory disorders. This work aimed at formulation of biodegradable VNP long-circulating nanoparticles utilizing Polyethylene glycol methyl ether-block-poly lactide-co-glycolide (PEG-PLGA) copolymer to surmount the drug drawbacks including low oral bioavailability and short elimination half-life. VNP nanoparticles were formulated using nanoprecipitation technique. A 2 factorial design was applied to assess the impact of formulation and process variables on the nanoparticles' characteristics. Statistical analysis revealed that nanoparticles size (Y) significantly increased with increasing PEG-PLGA amount (X), poly-vinyl alcohol concentration (X), and PLGA content (X), while decreased with increasing sonication time (X). Furthermore, the entrapment efficiency (Y) was positively affected by both PEG-PLGA amount and PLGA content, while negatively affected by poly-vinyl alcohol concentration. The optimized formulation prepared using 200 mg of PEG-PLGA polymer (PEG: PLGA 2000: 4,500), 0.5% polyvinyl alcohol with sonication time of 60 s achieved spherical shape with particle size of 43 nm and drug entrapment of 82%. A significant bioavailability enhancement of VNP with marked prolongation of the in vivo systemic exposure of the drug and increased brain levels has also been achieved following intraperitoneal administration in Wistar rats. Thus, the optimized formulation could be regarded as a promising stealth nanocarrier that could surmount the drug pitfalls and enhance its brain delivery.
长春西汀(VNP)是一种半合成药物,用于治疗脑血管和记忆障碍。本工作旨在利用聚乙二醇甲醚嵌段聚乳酸-共-羟基乙酸(PEG-PLGA)共聚物来制备可生物降解的 VNP 长循环纳米粒,以克服药物的缺点,包括低口服生物利用度和短消除半衰期。采用纳米沉淀技术制备 VNP 纳米粒。采用 2 因素设计评估制剂和工艺变量对纳米粒特性的影响。统计分析表明,纳米粒粒径(Y)随 PEG-PLGA 用量(X)、聚乙烯醇浓度(X)和 PLGA 含量(X)的增加而显著增加,随超声时间(X)的增加而减小。此外,包封效率(Y)受 PEG-PLGA 用量和 PLGA 含量的正向影响,而受聚乙烯醇浓度的负向影响。采用 200mg PEG-PLGA 聚合物(PEG:PLGA 2000:4500)、0.5%聚乙烯醇、超声时间 60s 制备的优化处方,可得到粒径为 43nm、载药量为 82%的球形纳米粒。在 Wistar 大鼠中经腹腔给药后,VNP 的生物利用度显著提高,体内系统暴露时间延长,药物在脑内水平升高,表明优化后的制剂可作为一种有前途的隐形纳米载体,克服药物的缺陷,提高其脑内传递。